Valuation : Nanobiotix

Market Cap 1.7B 1.97B 1.6B 1.46B 2.73B 186B 2.74B 18.89B 7.33B 95.64B 7.41B 7.25B 308B P/E 2026 *
-81.6x
P/E 2027 * -141x
Enterprise Value 1.74B 2.03B 1.64B 1.5B 2.81B 191B 2.81B 19.4B 7.53B 98.23B 7.61B 7.45B 316B EV / Sales 2026 *
45.8x
EV / Sales 2027 * 41.5x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-1.93%
1 week-7.61%
Current month-3.46%
1 month-1.41%
3 months+8.20%
6 months+16.12%
Current year+71.79%
1 week 33.06
Extreme 33.06
37.04
1 month 32.02
Extreme 32.02
39.98
Current year 16.66
Extreme 16.66
47.66
1 year 7.16
Extreme 7.16
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%-7.61%+365.28%+281.11% 1.97B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -1.02%-0.28%+106.41%+128.69% 27.7B
Weighted average by Cap. -1.04%+0.06%+91.52%+129.10%

Financials

2026 *2027 *
Net sales 38.06M 44.23M 35.81M 32.71M 61.2M 4.18B 61.36M 423M 164M 2.14B 166M 162M 6.9B 42.83M 49.77M 40.29M 36.81M 68.86M 4.7B 69.04M 476M 185M 2.41B 187M 183M 7.77B
Net income -12.18M -14.15M -11.46M -10.46M -19.58M -1.34B -19.63M -135M -52.53M -685M -53.13M -51.98M -2.21B -52.44K -60.94K -49.34K -45.07K -84.31K -5.75M -84.54K -583K -226K -2.95M -229K -224K -9.51M
Net Debt 46M 53.46M 43.28M 39.54M 73.96M 5.05B 74.16M 511M 198M 2.59B 201M 196M 8.34B 76.4M 88.79M 71.88M 65.67M 123M 8.38B 123M 849M 330M 4.3B 333M 326M 13.86B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-09-04 €33.50 -1.93% 122,004
26-09-03 €34.16 -3.01% 96,955
26-09-02 €35.22 +5.13% 167,696
26-09-01 €33.50 -3.46% 163,768
26-08-31 €34.70 -4.30% 206,332
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.50EUR
Average target price
52.20EUR
Spread / Average Target
+55.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock